Achillion Pharmaceuticals , Nasdaq: ACHN
Develops novel treatments for infectious diseases, including HIV and Hepatitis C.
Industry: Health Care
First Day Return: +7.7%
ACHN
Develops novel treatments for infectious diseases, including HIV and Hepatitis C.
| IPO Data | |
|---|---|
| IPO Date | 10/25/2006 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $52 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | New Haven, CT, United States |
| Founded | 1998 |
| Employees at IPO | 65 |
| Website www.achillion.com | |
IPO News for Achillion Pharmaceuticals
Achillion Pharmaceuticals (ACHN) Performance
